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Abstract 
Ribavirin (RBV) is a guanosine analogue triazole most commonly used in the treatment 
of chronic hepatitis C (HCV) infection. Although its mechanism of action is a matter of 
debate, several possibilities have been proposed, including depletion of guanine 
nucleotides through inhibition of inosine monophosphate dehydrogenase (IMPDH). 
IMPDH has been shown to assemble into micron-scale rod- and ring-shaped structures 
(rods/rings or RR), also called “IMPDH filaments,” both in vitro and in vivo. Formation of 
RR structures can occur naturally, potentially to influence IMPDH activity, or when de 
novo guanosine monophosphate biosynthesis or IMPDH itself are inhibited by nutrient 
deprivation or drugs like RBV. Numerous studies have also reported the occurrence of 
autoantibodies targeting RR structures (anti-RR) in HCV patients previously treated or 
under treatment with interferon-α and ribavirin (IFN/RBV) combination therapy. For this 
brief study, we considered the strong association between RR autoantibodies and 
IFN/RBV treatment, and the lack of data assessing how RBV affects RR formation in a 
variety of tissues in vivo. First, RR structures formed in the spleen and pancreas of 
normal mice without any treatment. Then, in RBV-treated mice, we detected RR 
structures in a number of tissues, including stomach, liver, spleen, kidney, brain, skin, 
and cardiac and skeletal muscle. We made several intriguing observations: 
predominance of RR structures in the mucosa and submucosa layers of the stomach 
wall; a high proportion of RR-positive cells in the cerebral cortex, suggesting that RBV 
actually crosses the blood-brain barrier; and a higher ratio of rings to rods in the 
epidermis compared to the dermis layer of the skin. Screening for RR structures 
appears to be a useful method to track tissue penetration of RBV and the many RR-




In recent years, numerous studies have reported the occurrence of autoantibodies 
targeting micron-scale rod- and ring-shaped structures (rods/rings or RR, also called 
cytoophidia) in the cytoplasm of cells (Calise et al., 2014; Carcamo et al., 2014; 
Carcamo et al., 2011). The primary autoantigen of these rods/rings autoantibodies 
(anti-RR), and major component of RR structures, is the enzyme inosine 
monophosphate dehydrogenase (IMPDH) (Calise et al., 2018; Carcamo et al., 2011; 
Keppeke et al., 2015; Probst et al., 2013; Seelig et al., 2011). IMPDH catalyzes the 
rate-limiting step in de novo guanosine monophosphate (GMP) synthesis and is an 
important target for immunosuppressive and antiviral drugs. Some of these IMPDH 
inhibitors, such as azathioprine, mycophenolic acid, mizoribine, and ribavirin (RBV), are 
currently used by an array of patients around the world. In cultured cells, IMPDH 
inhibitors promote the rapid polymerization of IMPDH protein into RR structures 
(Carcamo et al., 2011; Gunter et al., 2008; Ji et al., 2006). Other drugs that target 
upstream or downstream of IMPDH to block GMP synthesis, such as acyclovir, 
methotrexate, and pemetrexed, cause similar RR formation (Calise et al., 2016b; 
Carcamo et al., 2014; Keppeke et al., 2016b). RR formation has also been 
demonstrated in the peripheral blood mononuclear cells (PBMCs) of patients taking 
azathioprine, mycophenolic acid, methotrexate, and RBV (Keppeke et al., 2016b). 
Based on the potency of these drugs, it is reasonable to investigate the extent of RR 
formation across tissues of living organisms. 
Despite the potential for a variety of drugs to cause RR formation in humans, RR 
autoantibodies are almost exclusively found in patients with chronic hepatitis C virus 
(HCV) infection that have been exposed to interferon-α and ribavirin (IFN/RBV) 
combination therapy (Calise et al., 2016a; Covini et al., 2012; Keppeke et al., 2012; 
Novembrino et al., 2014; Stinton et al., 2013). Remarkably, RR autoantibodies are not 
found in these same patients prior to treatment, and are detected only very rarely in 
other diseases or in healthy individuals (Calise et al., 2014; Climent et al., 2016). Thus, 
we have referred to the production of RR autoantibody as a human model of drug-
induced autoantibody generation, considering that the particular combination of 
IFN/RBV exposure and presence of HCV appears to enhance the immunogenicity of 
IMPDH. The drug-induced RR autoantibody production is extensively discussed 
elsewhere (Calise et al., 2015; Keppeke et al., 2016a).  
Even 40 years after the discovery of its broad antiviral activity, the mechanism of action 
of RBV in HCV treatment remains a matter of debate (Paeshuyse et al., 2011). Several 
modes of action have been proposed, such as the depletion of guanine nucleotides 
through inhibition of IMPDH, direct inhibition of viral RNA-dependent RNA 
polymerases, modulation of cellular and humoral immunity, or even the increased 
mutagenesis of HCV leading to non-infectious virions (Galli et al., 2018; Testoni et al., 
2014). Although recently developed direct-acting antivirals (DAAs) have promised 
better interferon-free sustained virological response for HCV patients, RBV seems to 
be important for many DAAs to exert their full clinical benefits (Welsch et al., 2012). 
RBV is a triazole analogue of guanosine, and its distribution in tissues is largely defined 
by the expression of nucleoside transporters shown to facilitate the uptake of RBV 
(Endres et al., 2009). However, improved understanding of the penetration of RBV into 
different tissues in vivo could be useful in elucidating its antiviral effects, especially 
since we do not know why RR autoantibodies are preferentially observed in IFN/RBV-
treated patients and seldom in patients receiving other RR-inducing drugs. 
For this brief study, we considered the strong association between RR autoantibodies 
and IFN/RBV treatment, and the lack of data assessing how RBV affects RR formation 
in a variety of tissues in vivo. To understand this, we treated mice with RBV, collected 
various tissues, and probed them with rabbit polyclonal anti-IMPDH and human anti-
RR positive serum. Strikingly, we detected RR structures in all tissues collected from 
RBV-treated mice, including stomach, liver, spleen, kidney, brain, skin, and cardiac and 
skeletal muscle tissues. In contrast, the distribution of RR structures in control 
untreated mice was restricted to the spleen and pancreas. 
 
Results/Discussion 
As a control for the experimental group, tissues from untreated mice were collected 
and probed with anti-IMPDH alone or double-stained with anti-IMPDH and anti-RR 
serum as described in Supplementary Table 1. No RR structures were detected in 
stomach, liver, kidney, brain, skin, or cardiac and skeletal muscle tissues (Fig. 1A, B 
and Supplementary Fig. 1). These data indicate that the widespread occurrence of RR 
structures in the tissues of RBV-treated mice was a result of the drug intake (Fig. 2).   
Surprisingly, we detected RR structures in 16% of cells in spleen sections from the 
untreated mice. Curiously, the structures appeared predominantly in the outer edges of 
the spleen near the capsule, but only in the red pulp (Fig. 1C, D, F). Since RR 
structures were not present in all cells in the red pulp, and several different types of 
blood cells can be found in this region, further studies must be done to identify exactly 
which cell types form the RR structures. 
A prior study demonstrated the presence of IMPDH-based RR structures in mouse 
pancreatic islet cells (Chang et al., 2015). The authors proposed that RR structure 
formation correlates with insulin secretion in pancreatic β cells, since insulin-
exocytosis-associated GTPases utilize GTP to promote insulin secretion. Although we 
did not analyze the pancreas in the RBV-treated mice, we did stain for IMPDH in 
untreated mouse pancreas, and found RR structures in 15% of cells (Fig. 1E, F). This 
reinforces the idea that RR structure formation may be a common occurrence in 
specific tissues in vivo, and thus RR structures are likely to be performing important 
physiological functions. 
We previously demonstrated that RR structures form in the PBMCs of HCV patients 
several months into RBV therapy (Keppeke et al., 2016b). To determine whether in 
vivo RR formation after RBV treatment is a widespread occurrence, rather than 
restricted to white blood cells, we treated mice with RBV, collected various tissues, and 
probed them with rabbit anti-IMPDH and human anti-RR serum (Supplementary Table 
1). Strikingly, we detected RR structures in all tissues collected from RBV-treated mice.  
In the stomach wall, although the overall proportion of cells with RR structures was 
high (58%), RR structures formed predominantly in the mucosa and submucosa layers 
(Fig. 2A, representative images and Fig. 2I, quantification of all tissues). This might be 
because these cells came into direct contact with the orally ingested RBV, which can 
rapidly cross the plasma membrane with the help of nucleoside transporters. 
Additionally, the muscularis layer of the stomach is smooth muscle, and the other 
muscle tissues we examined also showed a lower proportion of RR-positive cells (Fig. 
2I). It is worth mentioning that the RR structures were recognized by both anti-IMPDH 
and anti-RR serum with perfect colocalization, as exemplified in Fig. 2A′, reinforcing the 
IMPDH-based composition of RR and the previous observation that this anti-RR 
positive serum contains autoantibodies to IMPDH (Carcamo et al., 2011). 
The organ with the highest overall proportion of RR-positive cells was the liver (71%) 
(Fig. 2B, I). Recent evidence shows that RBV efficiently loads into the liver, with total 
hepatic metabolite concentrations exceeding maximal levels in plasma by 
approximately 30-fold (Babusis et al., 2018). This indicates that hepatocytes may trap 
phosphorylated RBV metabolites. We expected that RBV would have high penetration 
in the liver, considering its use in the treatment of chronic HCV, which primarily infects 
the liver. Additionally, in vitro tests showed that the proportion of RR-positive cells 
reflects the concentration of RR-inducing drugs, up to a certain level (Keppeke et al., 
2016b). 
The proportion of RR-positive cells was relatively low in the spleen (21%) and 
moderate in the kidney (39% of cells) (Fig. 2C, D, I). The renal excretion of RBV and its 
metabolites accounts for 40% of its clearance; the remainder is eliminated through the 
spleen via its principal metabolite, RBV triphosphate, which is captured in erythrocytes 
(Carrier et al., 2016). After ingestion, once inside the cells, RBV is phosphorylated by 
adenosine kinase into its active monophosphate, diphosphate, and triphosphate forms 
(Markland et al., 2000). RBV monophosphate binds and inhibits IMPDH, but it is not 
known if other phosphorylated forms of RBV contribute to RR formation (Gish, 2006). 
Intriguingly, we did not observe any difference between RR formation in the spleens of 
untreated (16% ± 3.8% of cells) and RBV-treated mice (21% ± 4.9%; p=0.45, Student’s 
t-test), and in both cases RR predominated in the red pulp. It might be that RBV 
monophosphate, which inhibits IMPDH and is presumably the major form of RBV that 
induces RR formation, does not reach significant levels in the spleen compared to RBV 
triphosphate. 
Cardiac and skeletal muscle sections also showed low overall proportions of RR-
positive cells, 13% and 24%, respectively (Fig. 2E, F, I). We recently demonstrated a 
positive correlation between the presence of RR structures and high cell proliferation 
rate, associated with increased demand for guanine nucleotides in cells (Keppeke et 
al., 2018). Cardiomyocytes and myofibers, the most common cells in cardiac and 
skeletal muscle, respectively, do not proliferate in mature muscle tissues. 
Consequently, demand for de novo guanine nucleotide biosynthesis is also likely to be 
low, as fiber cells prefer ATP instead of GTP as an energy source. This might explain 
why the observed proportions of RR structures were decreased in these tissues. 
However, it is interesting that RBV induced RR structure formation even in non-dividing 
muscle cells.  
The observed proportion of RR-positive cells in the cerebral cortex was 56% (Fig. 2G, 
I). RBV has been shown to be ineffective against several encephalitis viruses in mice 
after intraperitoneal, subcutaneous, or intramuscular injection (Bussereau et al., 1988; 
Sidwell et al., 1973), suggesting a failure of RBV to effectively cross the blood-brain 
barrier. Attempts have been made to conjugate RBV to cyclodextrin as a drug carrier, 
or find new administration routes, such as intranasal, to overcome this issue (Colombo 
et al., 2011; Jeulin et al., 2009). The presence of RR structures in brain cells suggests 
that RBV actually crosses the blood-brain barrier, although we do not know if the 
amount entering the brain is sufficient for antiviral action. The presence of RR 
structures could be an effective criterion to determine if RBV or other RR-inducing 
drugs (Keppeke et al., 2016b) cross the blood-brain barrier. 
In most tissues and cell lines, rods predominate over rings. In the skin, the overall 
percentage of RR-positive cells was 37%, but, unexpectedly, the proportion of rings 
(rather than rods) was higher in the epidermis (58% ± 6.3%) than dermis (17% ± 5.9%; 
p=0.002 by Student’s t test) (Fig. 2H, I). A higher proportion of rings was previously 
observed in mouse embryonic stem cells (~90%) in contrast to cancer cell lines (~20%) 
(Carcamo et al., 2011). Recently, we showed additional evidence that rods and rings 
are likely functionally equivalent, since rods can become rings, merge with rings, or the 
structure can initially form as a ring (Chang et al., 2018). The reason for and meaning 
of the predominance of rings over rods in a restricted set of tissues is currently 
unknown. Further examination of skin tissue in RBV-treated mice could improve our 
understanding of the conditions in which cells prefer to assemble either the rod or the 
ring form of the RR structures.  
 Conclusion 
Our main goal in this study was to evaluate if IMPDH-based RR formation occurs in 
other tissues and cell types beyond PBMCs, reported earlier in patients undergoing 
IFN/RBV therapy. We detected widespread in vivo assembly of RR structures in all 
tissues analyzed from RBV-treated mice. We made several original and intriguing 
observations: RR structures predominated in the mucosa and submucosa layers of the 
stomach; there was a high proportion of RR-positive cells in the cerebral cortex; and 
there was a higher proportion of rings over rods in the epidermis compared to the 
dermis in the skin. Additionally, we detected RR structures in restricted tissues of 
normal mice without any treatment. Adding to a previous report on the presence of RR-
positive pancreatic cells in untreated mice, we also discovered RR structures in the 
spleen, although we could not identify the specific cell type that formed RR structures 
in the red pulp. These data suggest that RR formation is a physiological process and 
may play an important role in the purine biosynthesis pathway under specific 
circumstances.  
In recent years, we and others have independently reported that a high percentage of 
chronic HCV patients treated with IFN/RBV produce autoantibodies against IMPDH or 
other undetermined components of RR structures, yielding a positive HEp-2 
immunofluorescence test for the RR pattern (Calise et al., 2015; Keppeke et al., 
2016a). Although we do not fully understand the clinical implications of producing RR 
autoantibodies and the widespread formation of RR structures after RBV intake, we 
would recommend caution be exercised in the use of this drug to avoid overdosage 
and unnecessary prolonged exposure. As shown in this study, RBV can induce RR 
structure formation in a variety of organs, not just the liver, with unknown 
consequences. We also want to point out that screening for RR structures could be a 
useful method to track tissue penetration of the many RR-inducing drugs we have 
previously identified (Keppeke et al., 2016b). 
 
Methods 
Six male, 8-week-old BALB/c mice were obtained for the study. Three were kept 
untreated as controls, while the other three were treated orally with ribavirin for three 
months (generic ribavirin, lot # 14030216, Farmanguinhos Laboratory / Fiocruz, Rio de 
Janeiro, Brazil). Ribavirin was diluted in the water supplied to the mice, which was 
replaced every three days. Considering the daily intake of water per mouse, ribavirin 
intake was equivalent to 0.4 mg/day, a bodyweight-based dose similar to the daily 
concentration used in the treatment of chronic HCV infection in humans. The mice 
were maintained at CEDEME, an experimental animal facility at Universidade Federal 
de São Paulo (UNIFESP). The study was approved by the Ethics Committee of 
UNIFESP (process number CEP 0987/11). 
After the three-month treatment, mice were sacrificed by CO2 asphyxiation and the 
organs/tissues collected were immediately frozen by dipping into liquid nitrogen. After 
being preserved with Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, CA, 
USA), the organs/tissues were stored in -80°C until 4 μm-thick cryosections could be 
cut and mounted on slides. The following parts were collected: part of the stomach 
wall, part of the liver, part of the pancreas, the entire spleen, the entire right kidney, 
part of the heart for cardiac muscle, part of the skeletal muscle from the right back leg, 
part of the frontal cortex of the brain, and part of the skin from the belly. 
Prior to indirect immunofluorescent staining, cryosections were removed from -80°C 
and incubated with 4% paraformaldehyde in PBS for 20 min, followed by blocking with 
1% bovine serum albumin for 1 h at room temperature (RT). Sections were then 
incubated for 1 h at RT with rabbit polyclonal anti-IMPDH2 antibody (12948-1-AP, 
Proteintech, Chicago, IL, USA) alone or together with a human serum It2006 with anti-
RR/IMPDH reactivity previously characterized (Carcamo et al., 2011), both diluted 
1:500 in PBS. After washing three times with PBS for 5 min, slides were incubated with 
Alexa Fluor 568-conjugated goat anti-rabbit IgG (A-11036, Thermo Fisher, Waltham, 
MA, USA) and DyLight 488-conjugated goat anti-human IgG (072-03-10-06, Kirkegaard 
& Perry Laboratories, Gaithersburg, MD, USA), both diluted 1:500 in PBS, for 40 min at 
RT in a dark wet chamber. After washing as before, the slides were sealed with 
Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA) 
and analyzed under 200X, 400X, or 1000X magnification with a Zeiss Axio Imager M2 
fluorescence microscope (Carl Zeiss Microscopy, Jena, Germany). 
For the quantification of cells that present RR structures, at least three images were 
captured for each tissue from each animal. The amount of cells quantified in each 
tissue is presented in Supplementary Table 1. The average percentage of RR-positive 
cells (across all 3 animals in each group) for each tissue is presented with the standard 
error of mean (SEM).  
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Figure 1. RR structures formed in the spleen and pancreas of untreated mice. 
Cryosections from untreated mice (n=3) were labeled with anti-IMPDH (red) or human 
anti-RR serum (green). (A, B) Stomach mucosa and liver sections showed no RR 
structures. (C, D) Spleen sections from untreated mice showed RR structures labeled 
by anti-RR serum (C) and by anti-IMPDH antibody (D). RR structures primarily formed 
in the outer edges of the spleen, in the red pulp near the capsule. (E) RR structures 
were also detected in pancreas sections. Scale bars: 50 µm in A, C, and D; 30 µm in E; 
10 µm in B, C’, D’, and E’. (F) Overall percentage of cells that formed RR structures in 
the different tissues analyzed. Error bars indicate SEM. Additionally to stomach and 
liver (A, B), representative images for the other tissues analyzed that did not show any 
RR structures are presented in Supplementary Figure 1.  
 
Figure 2. RBV induced assembly of RR structures in a variety of mouse tissues. 
Mice (n=3) were treated for three months with RBV before tissues were harvested and 
snap-frozen. Cryosections were labeled with anti-IMPDH (red) or human anti-RR 
serum (green). (A) Stomach wall sections showed numerous RR structures, primarily in 
the mucosa and submucosa layers. (B-F) RR structures were observed in sections of 
various organs (liver, spleen, and kidney) and muscle (cardiac and skeletal). (G) Brain 
sections showed RR formation predominantly in the cortical plate. (H) RR structure 
formation in skin sections. The epidermis layer showed a higher proportion of rings 
(58% ± 6.3%) than dermis (17% ± 5.9%; p=0.0021 by Student’s t test). Arrows indicate 
rods and arrowheads indicate rings in (A’), (G’) and (H’). Scale bars: 50 µm in A; 30 µm 
in G and H; 10µm in A’, B-F, G’, H’, and H”. (I) Overall percentage of cells with RR 
structures in the different tissues analyzed. Error bars indicate SEM. Liver, stomach, 
and brain were the tissues with the highest proportions (˃50%) of cells forming RR 
structures.   
